Please login to the form below
biosimilars
This page shows the latest biosimilars news and features for those working in and with pharma, biotech and healthcare.
Latest news
-
NCI head Sharpless named as interim FDA chief
therapies such as cell and gene therapies, whilst encouraging greater competition to products at the other end of their lifespan from generics and biosimilars.
-
Roche files Venclexta plus Gazyva in CLL
However, the added cost of this shift, and the availability of biosimilar rituximab (Gazyva’s precursor) will raise cost effectiveness objections from European payers.
-
FDA chief Scott Gottlieb to step down
The latter included a ‘name and shame’ list of companies which abused regulations to block generic and biosimilar competition..
-
NHS England’s medicines chief: stop ‘salami slicing’ and get faster market access
Conversely, he said the use of horizon scanning would be enhanced by NHS England – including understanding the entry of biosimilars and competitor products – while also providing new opportunities for strategic partnerships
-
Senate grilling makes pharma CEOs squirm, but give little ground
There was broad consensus among the pharma chiefs on some issues: they backed a plan to ban rebates to insurers and pass them on to patients, called for faster biosimilars uptake, ... This proposed legislation would clear barriers to faster generic
More from news
Approximately 133 fully matching, plus 278 partially matching documents found.
Latest Intelligence
-
Drug launches to watch in 2019
The world’s biggest selling drug, Humira, lost its market exclusivity in Europe to biosimilar competition in 2018, and AbbVie is well aware of the impending US patent expiry in 2022. ... Finally, 2019 will see a rapid increase in the uptake of Humira
-
Deal Watch October 2018
None of the other biosimilars in the agreement between the two companies, in the fields of oncology and immunology, are affected. ... Sandoz’s US business has retained its biosimilars, value‐added medicines and complex generics, including the
-
Innovation in merger control and the impact on the pharmaceutical sector
Specifically, Hospira was selling Inflectra, an infliximab biosimilar used to treat several chronic inflammatory diseases, notably the inflammation of Crohn’s disease, while Pfizer was in an advanced stage of developing ... its own biosimilar for
-
Nudge-nudge, think-think
The power of achieving the triad of capability, opportunity and peer endorsement is evidenced by a recent study into how to avoid retrograde outcomes when switching patients from biologics to biosimilars.
-
Immuno-oncology is fundamentally changing what value means, but how quickly can the pharma marketing, educational and service model change to reflect that?
In recent years, biosimilars (highly similar copies of biologic medicines) have taken large shares of many markets. ... They come with a reduced price, which could offer a very substantial point of differentiation, but then so do many other biosimilars
More from intelligence
Approximately 11 fully matching, plus 53 partially matching documents found.
Latest appointments
-
Ashfield, Health Unlimited and Ashley Communications add to their teams
Van Weperen was most recently at diabetes giant Novo Nordisk, where he worked on delivering insulin and GLP1 biosimilar defence strategies, leading Novo’s UK diabetes team.
-
Lilly bolsters its oncology team
Furthermore, she has been on the forefront of research in oncology vaccines, immuno-oncology and biosimilars, giving her the unique expertise that will be pivotal in helping us continue to develop
-
PharmaLex appoints Zabin Younes as associate director
She joins the group as an associate director and arrives from ERA Consulting - a biopharmaceutical consultancy based in the UK - where she picked up experience in the biosimilar development lifecycle. ... With experience spanning over 15 years, Younes’
-
GW Pharmaceuticals strengthens research and development team
Knappertz has previously held several leadership positions including vice president of clinical development for multiple sclerosis, oncology and biosimilar products at Teva, and numerous clinical and medical roles at Bayer and
-
Sandoz UK promotes Tim de Gavre to country head
Novartis’ generics and biosimilar division Sandoz has appointed Tim de Gavre as its new country head for the UK. ... Our combined portfolio of small molecule generics and biosimilars makes a significant different to medicines costs, and helps the NHS
More from appointments
Approximately 1 fully matching, plus 14 partially matching documents found.
Latest from PMHub
-
Live webinar: Navigating new frontiers: Ways to find space in the future RA market
their convenient oral administration advantage may override cost considerations that would otherwise favour biosimilar uptake. ... Uptake curve of JAKs compared to other new entrants and biosimilars.
-
NHS medicines optimisation milestone
Tackling variations in the uptake of biosimilars locally has been a key focus for RMOCs. ... The best biologics agenda and pharma. In line with the Commissioning Framework for Biological Medicines, NHS England, NHS Improvement and NHS Clinical
-
New local NHS models help to deliver integrated care
A classic example of the way in which this can be achieved can be seen in the development of some biosimilar medicines, which are moving away from infusion to subcutaneous injections
-
OPEN Access Consulting
What OPEN Access Consulting do:. We have unrivalled experience in the delivery of market access programmes from early phase insights to generic/biosimilar strategies. ... High-cost medicines. Rare diseases. Long-term conditions. Generic and biosimilar
-
The Biosimilar Challenge
These include the infliximab biosimilars Inflectra and Remsima, the etanercept biosimilar Benepali (launched last year) and biosimilars to adalimumab, filgrastim and bevacizumab preparing to launch on the horizon. . ... Biosimilar Cost-Savings in Reality
More from PMHub
Approximately 13 fully matching, plus 23 partially matching documents found.
Featured jobs
-
Health Consultant - Brand Comms
-
Competitive Salary
- Home based, Senior Medical Writer, Medical Communications
-
Excellent package
- Freelance Senior Account Manager / Account Director - Healthcare...
-
£350-400 depending on experience
-
Account Director, Medical Education
-
Salary TBC
- Scientific Director – Medical Communications
-
Salary TBC
-
Digital Account Director
-
Salary TBC
- Senior Account Manager, Medical Communications, London
-
Excellent package
- EU Head of Business Development and Client Service
-
Exceptional packge and bonus
- Account Manager, Medical Communications and Marketing
-
£30, 000 – £40, 000 benefits and bonus
- Home-based Senior Medical Writer – Med Ed
-
Salary TBC
-
Creative/ Medical Writer
-
Circa £35, 000 With Benefits
- Scientific Director – Medical Communications - New York or Remot...
-
$100000 - $150000
- Freelance AM/ AD Healthcare Advertising
-
£350-400 depending on experience
-
Senior Medical Writer
-
Salary TBC
- Science Writer, Healthcare Advertising Agency
-
£40, 000 - 45, 000 DOE benefits,
Subscribe to our email news alerts
- Blood disorder specialists Imara raises $63m
- NICE wants to stop saying ‘no’ – but needs pharma’s co-operation
- Three questions that should anchor your brand strategy
- Allergy Tx hit hard as birch pollen product stumbles
- Sanofi gets cardio outcomes claim for Praluent in EU
- Keytruda adds another NSCLC approval in Europe
PMHub
emotive.
emotive. is an award-winning healthcare communications agency working with leading global and EMEA companies in life sciences including medical device...
Latest intelligence
- “Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
- The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...
- The Future of Pharma sales: fast forward to 2029
- Change is inevitable, and necessary, for growth in business....
- International Women's Day - 8 March 2019
- International Women's Day has been celebrated since its inception in 1911. But how far have we come?...
Quick links
Infographics
